Adult Vaccines Market Report 2025

The adult vaccines market size has grown strongly in recent years. It will grow from $22.82 billion in 2024 to $24.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing aging population, government vaccination programs, growing awareness of preventive healthcare, vaccine development and innovation, public health campaigns.

The adult vaccines market size is expected to see strong growth in the next few years. It will grow to $35.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of new infectious threats, increasing focus on immunization registries, rising threat of antimicrobial resistance, global efforts for pandemic preparedness, shift toward personalized vaccines, increased focus on maternal immunization. Major trends in the forecast period include digital health integration, technological advancements in vaccine production, collaborations between governments and pharmaceutical companies, advancements in vaccine delivery technologies, expanding immunization programs.

The rising incidence of contagious diseases is propelling the adult vaccine market forward. Contagious diseases are those that can be transmitted from one person to another. Vaccines enable individuals to develop immunity against these diseases, making them a highly effective means of combating infections. For example, in March 2023, the Centers for Disease Control and Prevention, a national public health agency based in the United States, reported that in 2022, there were 8,300 cases of tuberculosis in the country, an increase from 7,874 cases in 2021. The incidence of TB in 2022 rose slightly to 2.5 per 100,000 individuals, compared to 2.4 in 2021. Therefore, the increasing prevalence of contagious diseases is driving the growth of the adult vaccine market.

The rise in healthcare expenditure has bolstered the growth of the adult vaccine market. Healthcare expenditure refers to the overall costs associated with healthcare services provided to a population. An increase in healthcare spending often results in more funding for medical research and development. By investing in vaccination programs and enhancing access to vaccines, healthcare systems can alleviate the burden of preventable diseases and improve the overall health of the population. Moreover, adult vaccination can lead to substantial cost savings by decreasing healthcare utilization and the necessity for expensive treatments. For example, in November 2023, the Canadian Institute for Health Information, a health organization based in Canada, projected that Canada's total health expenditure in 2023 would reach $344 billion, representing an increase of over $9 billion compared to 2022. Therefore, the rise in healthcare expenditure has positively influenced the growth of the adult vaccine market.

Product innovation emerges as a pivotal trend driving the evolution of the adult vaccines market. Major industry players are introducing innovative products to fortify their market presence. For instance, in August 2022, GSK, a UK-based biopharma company, partnered with IQVIA, an India-based global provider of advanced analytics and clinical research services, to launch Vaccine Track. This pioneering data trend platform aims to enhance adult vaccination efforts nationwide by providing real-time, pertinent data trends that focus on improving public health initiatives. The advent of such innovative tools underscores the industry's commitment to leveraging data and technology to advance adult vaccination strategies and address prevailing healthcare challenges.

Prominent players within the adult vaccine market are emphasizing strategic collaborations aimed at the development and commercialization of personalized cancer vaccines. These collaborations, centered on mutual objectives, are pivotal business relationships between multiple companies. For instance, in October 2022, Merck & Co., Inc., an American multinational pharmaceutical company, partnered with Moderna, a US-based pharmaceutical and biotechnology company, to collectively advance and commercialize the personalized cancer vaccine mRNA-4157/V940. Under their existing collaboration and license agreement, both entities will collaborate on the development and commercialization of mRNA-4157/V940, which is currently undergoing assessment in a Phase 2 clinical trial conducted by Moderna. This vaccine is being evaluated alongside KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment for high-risk melanoma patients.

In August 2022, GSK, a UK-based pharmaceutical giant, acquired Affinivax, Inc., a US-based clinical-stage biopharmaceutical company, in a deal of undisclosed value. This strategic acquisition aligns with GSK's broader strategy of bolstering its portfolio in specialty medicines and vaccines, particularly focusing on innovative vaccine candidates for pneumococcal disease. Affinivax, Inc., known for its pioneering work in next-generation pneumococcal vaccines and adult vaccines based on the Multiple Antigen Presenting System (MAPS) platform technology, is expected to complement GSK's efforts in advancing cutting-edge vaccine solutions. This strategic move underscores GSK's commitment to driving advancements in adult vaccines and strengthening its position within the healthcare landscape.

Major companies operating in the adult vaccines market include GlaxoSmithKline PLC, Merck & Co, Sanofi Pasteur, Pfizer Inc, Commonwealth Serum Laboratories Limited, Johnson & Johnson, Serum Institute of India, AstraZeneca PLC, Novartis AG, Protein Sciences Corporation, Emergent BioSolutions Inc., Bavarian Nordic A/S, Dynavax Technologies Corporation, Novavax Inc, Medimmune LLC, BioNTech SE, Moderna, Inovio Pharmaceuticals, Sinovac, Valneva Se, Biological E Limited, Panacea Biotec, Shenzhen Kangtai Biological Products, Beijing Tiantan Biological Products, Hualan Biological Engineering, Chengdu Institute of Biological Products, Bharat Biotech International Limited, Takeda Pharmaceutical Company Limited.

North America was the largest region in the adult vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the adult vaccines market during the forecast period. The regions covered in the adult vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adult vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adult vaccines are immunizations administered to adults to stimulate an immune response against disease-causing pathogens. These vaccines play a crucial role in the prevention and treatment of various diseases affecting adults, including influenza, pneumococcal disease, and herpes.

The primary types of adult vaccines include monovalent and multivalent options. A monovalent vaccine contains the mRNA component of a single virus, triggering an immune response against a specific antigen. Various technologies are employed in the development of adult vaccines, including live attenuated vaccines, inactivated viral or bacterial vaccines, toxoid vaccines, recombinant vaccines, and conjugate vaccines. These vaccines find applications in preventing diseases such as influenza, diphtheria, pertussis, tetanus (dPT), human papillomavirus, shingles (zoster), pneumococcal disease, and hepatitis. Healthcare firms and hospitals are key users of these vaccines.

The adult vaccines market research report is one of a series of new reports that provides adult vaccines market statistics, including adult vaccines industry global market size, regional shares, competitors with a adult vaccines market share, detailed adult vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the adult vaccines industry. This adult vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult vaccines market consists of sales of mRNA vaccines and viral vector vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.